These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 22686691)

  • 1. Combination therapy with finasteride and low-dose dutasteride in the treatment of androgenetic alopecia.
    Boyapati A; Sinclair R
    Australas J Dermatol; 2013 Feb; 54(1):49-51. PubMed ID: 22686691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.
    Gubelin Harcha W; Barboza Martínez J; Tsai TF; Katsuoka K; Kawashima M; Tsuboi R; Barnes A; Ferron-Brady G; Chetty D
    J Am Acad Dermatol; 2014 Mar; 70(3):489-498.e3. PubMed ID: 24411083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride.
    Olsen EA; Hordinsky M; Whiting D; Stough D; Hobbs S; Ellis ML; Wilson T; Rittmaster RS;
    J Am Acad Dermatol; 2006 Dec; 55(6):1014-23. PubMed ID: 17110217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of 3% minoxidil versus combined 3% minoxidil / 0.1% finasteride in male pattern hair loss: a randomized, double-blind, comparative study.
    Tanglertsampan C
    J Med Assoc Thai; 2012 Oct; 95(10):1312-6. PubMed ID: 23193746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of 5α-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit-risk assessment of finasteride and dutasteride.
    Gupta AK; Charrette A
    J Dermatolog Treat; 2014 Apr; 25(2):156-61. PubMed ID: 23768246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective treatment of female androgenic alopecia with dutasteride.
    Olszewska M; Rudnicka L
    J Drugs Dermatol; 2005; 4(5):637-40. PubMed ID: 16167423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonsurgical therapy for hair loss.
    Nusbaum AG; Rose PT; Nusbaum BP
    Facial Plast Surg Clin North Am; 2013 Aug; 21(3):335-42. PubMed ID: 24017975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hair restoration approaches for early onset male androgenetic alopecia.
    Bhatti HA; Basra MK; Patel GK
    J Cosmet Dermatol; 2013 Sep; 12(3):223-31. PubMed ID: 23992164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral finasteride improved the quality of life of androgenetic alopecia patients.
    Yamazaki M; Miyakura T; Uchiyama M; Hobo A; Irisawa R; Tsuboi R
    J Dermatol; 2011 Aug; 38(8):773-7. PubMed ID: 21806672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapy of androgenetic alopecia with finasteride. What must be considered in consultation and drug prescribing].
    Wolff H; Kunte C
    MMW Fortschr Med; 1999 Sep; 141(37):38-40. PubMed ID: 10897972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Global photographic assessment of men aged 18 to 60 years with male pattern hair loss receiving finasteride 1 mg or placebo.
    Olsen EA; Whiting DA; Savin R; Rodgers A; Johnson-Levonas AO; Round E; Rotonda J; Kaufman KD;
    J Am Acad Dermatol; 2012 Sep; 67(3):379-86. PubMed ID: 22325459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delaying treatment in male-pattern hair loss affects the therapeutic response.
    Rushton DH; Gilkes JJ
    Clin Exp Dermatol; 2011 Mar; 36(2):204-5. PubMed ID: 20659117
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison of oral minoxidil, finasteride, and dutasteride for treating androgenetic alopecia.
    Gupta AK; Talukder M; Williams G
    J Dermatolog Treat; 2022 Nov; 33(7):2946-2962. PubMed ID: 35920739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-α reductase inhibitors and prostate cancer prevention: where do we turn now?
    Hamilton RJ; Freedland SJ
    BMC Med; 2011 Sep; 9():105. PubMed ID: 21920036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgens and hair loss.
    Alsantali A; Shapiro J
    Curr Opin Endocrinol Diabetes Obes; 2009 Jun; 16(3):246-53. PubMed ID: 19396986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What's New in Therapy for Male Androgenetic Alopecia?
    Saceda-Corralo D; Domínguez-Santas M; Vañó-Galván S; Grimalt R
    Am J Clin Dermatol; 2023 Jan; 24(1):15-24. PubMed ID: 36169916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the treatment of male androgenetic alopecia: a brief review of finasteride studies.
    Whiting DA
    Eur J Dermatol; 2001; 11(4):332-4. PubMed ID: 11399540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of efficacy and safety of finasteride 1 mg in 3177 Japanese men with androgenetic alopecia.
    Sato A; Takeda A
    J Dermatol; 2012 Jan; 39(1):27-32. PubMed ID: 21980923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia.
    Price VH; Roberts JL; Hordinsky M; Olsen EA; Savin R; Bergfeld W; Fiedler V; Lucky A; Whiting DA; Pappas F; Culbertson J; Kotey P; Meehan A; Waldstreicher J
    J Am Acad Dermatol; 2000 Nov; 43(5 Pt 1):768-76. PubMed ID: 11050579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of sexual function with an international index of erectile function in subjects taking finasteride for androgenetic alopecia.
    Tosti A; Pazzaglia M; Soli M; Rossi A; Rebora A; Atzori L; Barbareschi M; Benci M; Voudouris S; Vena GA
    Arch Dermatol; 2004 Jul; 140(7):857-8. PubMed ID: 15262698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.